OncoImmunity AS has been acquired by renowned Japanese IT and network company, NEC Corporate. OncoImmunity AS develops software that identifies neoantigen targets for truly personalized cancer vaccines, cell therapies and optimal patient selection for cancer immunotherapy clinical trials.
GJE provided OncoImmunity AS with IP-related due diligence support during the acquisition and continues to manage the company’s patent portfolio. The GJE team is led by partner Matt Hoyles.
To read the full press release, please follow this link.
Related resources
Cultivating Christmas: Lab-To-Table Delicacies You Won’t Want to Miss This Year!
As we approach the end of 2023, the lure of innovative high-tech food products seems greater than ever....
Managing a Trade Mark Portfolio – Supporting Efficiency and Enhancing Growth: Part 1
For mature businesses with extensive IP portfolios, having a clear and signposted IP strategy in place saves money...
Is the Hague System Underused by Design Applicants?
The latest Hague Yearly Review [1] of industrial designs filed under the Hague system shows that the number...